The Daily Papule

JEADV

IADVL consensus recommendations on Trichophyton indotineae infections

Using modified Delphi method.

Khurana A, Jayaraman J, Adil M, Chowdhary A, Bhunia D, Sardana K, Venkata Chalam K, Rudramurthy SM, Rengasamy M, Shenoy M, Patel NKH, Patro N, Shafiq N, Poojary S, Bansal S, Verma S, Dogra S

Journal of the European Academy of Dermatology and VenereologyIn the feed 1 Oct 2026, published online 1 Oct 2026, issue 2026 Oct 01, added to PubMed 1 Oct 2026

Topics: Infections & infestationsPediatric dermatology

Abstract

BACKGROUNDTrichophyton indotineae has emerged as a significant novel species causing tinea corporis/cruris/faciei, with established endemicity in a few regions and potential for expanding endemic zones in future.

OBJECTIVESWe aimed to develop consensus on disease definitions, diagnosis and treatment of T. indotineae infection.

METHODSRelevant literature from 2017 onwards was analysed and presented to the panel of dermatology experts, followed by circulation of a structured Google questionnaire encompassing various aspects of systemic and topical treatment, including special scenarios. Repeat rounds with modified questions were conducted in domains where (75%) consensus was not achieved, till a maximum of three rounds. Disease definitions were arrived at by discussion among clinical experts. Mycological (diagnostic) guidelines were formulated by the expert mycology members through peer review of each other's drafts.

RESULTSThe panel comprised 14 dermatologists, 2 mycologists and 1 pharmacologist. Disease definitions for clinical and research use are presented. KOH smear testing is recommended in clinically doubtful cases, whereas culture, antifungal susceptibility testing and sequencing are recommended for monitoring trends of prevalent species and drug susceptibility in specialized mycology laboratories. A total of 87 therapeutic questions were put to the 14 dermatologists. Key therapeutic recommendations include the use of itraconazole (ITZ) as a first-line systemic agent and terbinafine (TRB) (higher dose) as a second line, switching systemic antifungal in case of inadequate response at 4 weeks, use of prolonged treatment (till cure) and treatment of relapses with the same regimen as used for initial treatment. Recommendations for treatment monitoring and treatment in special scenarios such as paediatric patients, pregnancy, lactation, renal or hepatic dysfunction, cardiac failure and patients on topical/systemic steroids or immunosuppressives are presented.

CONCLUSIONSThe panel has made recommendations on clinical and diagnostic aspects of T. indotineae infections, which would improve patient outcomes and foster academic communication and research.

Abstract from PubMed

PMID 42820589 · DOI 10.1111/jdv.70693